Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

被引：30
|
作者：
Kaufman, Jonathan L. [1 ]
Usmani, Saad Z. [2 ]
San-Miguel, Jesus [3 ]
Bahlis, Nizar [4 ]
White, Darrell J. [5 ,6 ]
Benboubker, Lotfi [7 ]
Cook, Gordon [8 ,9 ]
Leiba, Merav [10 ]
Ho, P. Joy
Kim, Kihyun
Takezako, Naoki
Moreau, Philippe [11 ]
Krevvata, Maria [12 ]
Pei, Huiling [13 ]
Ukropec, Jon [14 ]
Renaud, Thomas [15 ]
Trivedi, Sonali [12 ]
Kobos, Rachel [15 ]
Dimopoulos, Meletios A. [16 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Carolinas HealthCare Syst, Levine Canc Inst, Charlotte, NC USA
[3] Clin Univ Navarra CIMA, IDISNA, CIBERONC, Pamplona, Spain
[4] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada
[5] Dalhousie Univ, Halifax, NS, Canada
[6] QEII Hlth Sci Ctr, Halifax, NS, Canada
[7] Ctr Hosp Reg Univ CHRU, Serv Hematol & Therapie Cellulaire, Hop Bretonneau, Tours, France
[8] Teaching Hosp NHS Trust, St Jamess Inst Oncol, Leeds, W Yorkshire, England
[9] Univ Leeds, Leeds, W Yorkshire, England
[10] Ben Gurion Univ Negev, Assuta Univ Hosp, Fac Hlth Sci, Beer Sheva, Israel
[11] Univ Hosp Hotel Dieu, Hematol, Nantes, France
[12] Janssen Res & Dev LLC, Spring House, PA USA
[13] Janssen Res & Dev LLC, Titusville, NJ USA
[14] Janssen Global Med Affairs, Horsham, PA USA
[15] Janssen Res & Dev, Raritan, NJ USA
[16] Natl & Kapodistrian Univ Athens, Athens, Greece
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-123483
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1866
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
    Moreau, Philippe
    Facon, Thierry
    Usmani, Saad
    Bahlis, Nizar Jacques
    Raje, Noopur
    Plesner, Torben
    Orlowski, Robert Z.
    Basu, Supratik
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Carson, Robin
    Borgsten, Fredrik
    Kumar, Shaji K.
    BLOOD, 2022, 140 : 7297 - 7300
  • [22] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
    Moreau, P.
    Facon, T.
    Usmani, S. Z.
    Bahlis, N.
    Raje, N.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Wang, G.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Kumar, S. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 238 - 238
  • [23] Evaluation of Sustained Minimal Residual Disease (MRD) Negativity in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone (D-Rd) or Bortezomib Plus Dexamethasone (D-Vd): Analysis of Pollux and Castor
    Avet-Loiseau, Herve
    San-Miguel, Jesus F.
    Casneuf, Tineke
    Iida, Shinsuke
    Lonial, Sagar
    Usmani, Saad Z.
    Spencer, Andrew
    Moreau, Philippe
    Plesner, Torben
    Weisel, Katja
    Ukropec, Jon
    Okonkwo, Linda
    Trivedi, Sonali
    Velas, Christopher Joseph
    Qin, Xiang
    Qi, Ming
    Chiu, Christopher
    Bahlis, Nizar
    BLOOD, 2018, 132
  • [24] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study
    Moreau, P.
    Facon, T.
    Usmani, S. Z.
    Bahlis, N.
    Raje, N.
    Plesner, T.
    Orlowski, R. Z.
    Basu, S.
    Nahi, H.
    Hulin, C.
    Quach, H.
    Goldschmidt, H.
    O'Dwyer, M.
    Perrot, A.
    Venner, C. P.
    Weisel, K.
    Tiab, M.
    Macro, M.
    Frenzel, L.
    Leleu, X.
    Pei, H.
    Krevvata, M.
    Carson, R.
    Borgsten, F.
    Kumar, S. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 316 - 317
  • [25] Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.
    Spencer, Andrew
    Moreau, Philippe
    Mateos, Maria-Victoria
    Goldschmidt, Hartmut
    Suzuki, Kenshi
    Levin, Mark-David
    Sonneveld, Pieter
    Yoon, Sung-Soo
    Usmani, Saad Zafar
    Weisel, Katja
    Reece, Donna Ellen
    Ahmadi, Tahamtan
    Pei, Huiling
    Mayo, Wendy Garvin
    Gai, Xue
    Carey, Jodi
    Carson, Robin L.
    Dimopoulos, Meletios A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux
    Usmani, Saad Z.
    Dimopoulos, Meletios A.
    Belch, Andrew
    White, Darrell
    Benboubker, Lofti
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Khokhar, Nushmia Z.
    Guckert, Mary
    Wu, Kaida
    Qin, Xiang
    Casneuf, Tineke
    Chiu, Christopher
    Sasser, A. Kate
    San-Miguel, Jesus
    BLOOD, 2016, 128 (22)
  • [27] Phase 3 ELOQUENT-2 study: extended 4-year follow-up of Elotuzumab plus lenalidomide/ dexamethasone vs lenalidomide/ dexamethasone in relapsed/ refractory multiple myeloma
    Weisel, K.
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 35 - 35
  • [28] PHASE 3 ELOQUENT-2 STUDY: EXTENDED 4-YEAR FOLLOW-UP OF ELOTUZUMAB PLUS LENALIDOMIDE/DEXAMETHASONE VS LENALIDOMIDE/DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Dimopoulos, M. A.
    Lonial, S.
    White, D.
    Moreau, P.
    Mateos, M. -V.
    San Miguel, J.
    Anderson, K. C.
    Shpilberg, O.
    Grosicki, S.
    Spicka, I.
    Walter-Croneck, A.
    Magen, H.
    Belch, A.
    Reece, D. E.
    Beksac, M.
    Mekan, S.
    Sy, O.
    Singhal, A. K.
    Richardson, P. G.
    Weisel, K.
    HAEMATOLOGICA, 2017, 102 : 167 - 168
  • [29] Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
    Suzuki, Kenshi
    Dimopoulos, Meletios A.
    Takezako, Naoki
    Okamoto, Shinichiro
    Shinagawa, Atsushi
    Matsumoto, Morio
    Kosugi, Hiroshi
    Yoon, Sung-Soo
    Huang, Shang-Yi
    Qin, Xiang
    Qi, Ming
    Iida, Shinsuke
    BLOOD CANCER JOURNAL, 2018, 8
  • [30] Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
    Kenshi Suzuki
    Meletios A. Dimopoulos
    Naoki Takezako
    Shinichiro Okamoto
    Atsushi Shinagawa
    Morio Matsumoto
    Hiroshi Kosugi
    Sung-Soo Yoon
    Shang-Yi Huang
    Xiang Qin
    Ming Qi
    Shinsuke Iida
    Blood Cancer Journal, 8
12345